Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | SI | P14410 | 1/20 | 0.37 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.37 |
| ▸ | KDM5A | P29375 | 2/20 | 0.34 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MVD | P53602 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8378681 | 0.83 | KMT2A (0.54) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL1692353 | 0.82 | KMT2A (0.50) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL16790891 | 0.82 | MEN1 (0.50) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL6405180 | 0.82 | MEN1 (0.50) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL15623091 | 0.80 | MEN1 (0.48) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL30418438 | 0.80 | MEN1 (0.48) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL21775914 | 0.77 | MEN1 (0.45) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL10260566 | 0.76 | — | — | |
| SCHEMBL15307493 | 0.75 | MEN1 (0.44) | KMT2AMEN1TSHRHSD17B10MGAM | |
| SCHEMBL12848227 | 0.75 | MEN1 (0.44) | KMT2AMEN1TSHRHSD17B10MGAM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1994000-B1 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2017-08-23 | — | — | EP | claimed |
| EP-2173739-B1 | SUBSTITUTED CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2013-07-31 | — | — | EP | claimed |
| WO-2011051484-A1 | FLUORESCENCE DYES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENLICHEN RECHTS (DE) | 2011-05-05 | — | — | WO | claimed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | claimed |
| EP-4374877-A2 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-29 | — | — | EP | disclosed |
| EP-3928779-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-03-06 | — | — | EP | disclosed |
| EP-3928779-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR AND PHOSPHORUS ADSORBENT FOR USE IN THE PREVENTION, TREATMENT OR SUPPRESSION OF CHRONIC KIDNEY DISEASE, ARTERIOSCLEROSIS ASSOCIATED WITH VASCULAR CALCIFICATION, OR ECTOPIC CALCIFICATION. | Chugai Seiyaku Kabushiki Kaisha (JP) | 2021-12-29 | — | — | EP | disclosed |
| EP-3192511-B1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2021-07-14 | — | — | EP | disclosed |
| EP-3757093-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2020-12-30 | — | — | EP | disclosed |
| EP-2975030-B1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-07-15 | — | — | EP | disclosed |
| EP-1994000-B1 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA BV (NL) | 2017-08-23 | — | — | EP | disclosed |
| EP-3192511-A1 | PHARMACEUTICAL CONTAINING SODIUM-DEPENDENT PHOSPHATE TRANSPORTER INHIBITOR | Chugai Seiyaku Kabushiki Kaisha (JP) | 2017-07-19 | — | — | EP | disclosed |
| US-9499553-B2 | Dihydropyridazine-3,5-dione derivative and pharmaceuticals containing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-11-22 | — | — | US | disclosed |
| EP-2975030-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-01-07 | — | — | US | disclosed |
| US-8940784-B2 | Water-soluble CC-1065 analogs and their conjugates | SYNTARGA B.V. (NL) | 2015-01-27 | — | — | US | disclosed |
| WO-2011051484-A1 | FLUORESCENCE DYES | GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENLICHEN RECHTS (DE) | 2011-05-05 | — | — | WO | disclosed |
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | Georg-August-Universität Göttingen Stiftung öffentlichen Rechts (ohne Bereich Humanmedizin) (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-1994000-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | Syntarga B.V. (NL) | 2008-11-26 | — | — | EP | disclosed |
| WO-2007089149-A2 | WATER-SOLUBLE CC-1065 ANALOGS AND THEIR CONJUGATES | SYNTARGA B.V. (NL) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318668-A1 | Water-Soluble CC-1065 Analogs and Their Conjugates | PCNA, DCK, BAD | KMT2A 1501/4885MEN1 2080/4885TSHR 3098/4885 |
| US-20160002251-A1 | DIHYDROPYRIDAZINE-3,5-DIONE DERIVATIVE AND PHARMACEUTICALS CONTAINING THE SAME | SLC9A5, SLC5A2, SLC5A1 | KMT2A 2776/4885MEN1 2283/4885TSHR 2656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.